Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology

Parag A. Majmudar, Steven C. Schallhorn, John B. Cason, Kendall E. Donaldson, George D. Kymionis, Roni M. Shtein, Steven Verity, Ayad A. Farjo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective To review the published literature assessing the efficacy and safety of mitomycin-C (MMC) as an adjunctive treatment in corneal surface excimer laser ablation procedures. Methods Literature searches of the PubMed and Cochrane Library databases were last conducted on August 19, 2014, without language or date limitations. The searches retrieved a total of 239 references. Of these, members of the Ophthalmic Technology Assessment Committee Refractive Management/Intervention Panel selected 26 articles that were considered to be of high or medium clinical relevance, and the panel methodologist rated each article according to the strength of evidence. Ten studies were rated as level I evidence, 5 studies were rated as level II evidence, and the remaining 11 studies were rated as level III evidence. Results The majority of the articles surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation procedures. When MMC is applied in the appropriate concentration and confined to the central cornea, the incidence of post-surface ablation haze is decreased. Although a minority of studies that evaluated endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcomes were reported. Conclusions Over the past 15 years, the use of MMC during surgery in surface ablation has become widespread. There is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against haze in higher myopic ablations. Although there are reports of decreased endothelial counts after the administration of MMC during surgery, the clinical significance of this finding remains uncertain, because no adverse outcomes were reported with as much as 5 years of follow-up. Optimal dosage, effectiveness as prophylaxis in lower myopic and hyperopic ablations, and long-term safety, particularly in eyes with reduced corneal endothelial cell counts from prior intraocular surgery, have yet to be established.

Original languageEnglish (US)
Pages (from-to)1085-1095
Number of pages11
JournalOphthalmology
Volume122
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Ablation Techniques
Excimer Lasers
Laser Therapy
Mitomycin
Ophthalmology
Endothelial Cells
Cell Count
Safety
Biomedical Technology Assessment
PubMed
Cornea
Libraries
Language
Databases
Incidence
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Majmudar, P. A., Schallhorn, S. C., Cason, J. B., Donaldson, K. E., Kymionis, G. D., Shtein, R. M., ... Farjo, A. A. (2015). Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology. Ophthalmology, 122(6), 1085-1095. https://doi.org/10.1016/j.ophtha.2015.01.019

Mitomycin-C in corneal surface excimer laser ablation techniques : A report by the American academy of ophthalmology. / Majmudar, Parag A.; Schallhorn, Steven C.; Cason, John B.; Donaldson, Kendall E.; Kymionis, George D.; Shtein, Roni M.; Verity, Steven; Farjo, Ayad A.

In: Ophthalmology, Vol. 122, No. 6, 01.06.2015, p. 1085-1095.

Research output: Contribution to journalArticle

Majmudar, PA, Schallhorn, SC, Cason, JB, Donaldson, KE, Kymionis, GD, Shtein, RM, Verity, S & Farjo, AA 2015, 'Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology', Ophthalmology, vol. 122, no. 6, pp. 1085-1095. https://doi.org/10.1016/j.ophtha.2015.01.019
Majmudar PA, Schallhorn SC, Cason JB, Donaldson KE, Kymionis GD, Shtein RM et al. Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology. Ophthalmology. 2015 Jun 1;122(6):1085-1095. https://doi.org/10.1016/j.ophtha.2015.01.019
Majmudar, Parag A. ; Schallhorn, Steven C. ; Cason, John B. ; Donaldson, Kendall E. ; Kymionis, George D. ; Shtein, Roni M. ; Verity, Steven ; Farjo, Ayad A. / Mitomycin-C in corneal surface excimer laser ablation techniques : A report by the American academy of ophthalmology. In: Ophthalmology. 2015 ; Vol. 122, No. 6. pp. 1085-1095.
@article{c80d50a26eb14d37abade5b580419bd7,
title = "Mitomycin-C in corneal surface excimer laser ablation techniques: A report by the American academy of ophthalmology",
abstract = "Objective To review the published literature assessing the efficacy and safety of mitomycin-C (MMC) as an adjunctive treatment in corneal surface excimer laser ablation procedures. Methods Literature searches of the PubMed and Cochrane Library databases were last conducted on August 19, 2014, without language or date limitations. The searches retrieved a total of 239 references. Of these, members of the Ophthalmic Technology Assessment Committee Refractive Management/Intervention Panel selected 26 articles that were considered to be of high or medium clinical relevance, and the panel methodologist rated each article according to the strength of evidence. Ten studies were rated as level I evidence, 5 studies were rated as level II evidence, and the remaining 11 studies were rated as level III evidence. Results The majority of the articles surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation procedures. When MMC is applied in the appropriate concentration and confined to the central cornea, the incidence of post-surface ablation haze is decreased. Although a minority of studies that evaluated endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcomes were reported. Conclusions Over the past 15 years, the use of MMC during surgery in surface ablation has become widespread. There is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against haze in higher myopic ablations. Although there are reports of decreased endothelial counts after the administration of MMC during surgery, the clinical significance of this finding remains uncertain, because no adverse outcomes were reported with as much as 5 years of follow-up. Optimal dosage, effectiveness as prophylaxis in lower myopic and hyperopic ablations, and long-term safety, particularly in eyes with reduced corneal endothelial cell counts from prior intraocular surgery, have yet to be established.",
author = "Majmudar, {Parag A.} and Schallhorn, {Steven C.} and Cason, {John B.} and Donaldson, {Kendall E.} and Kymionis, {George D.} and Shtein, {Roni M.} and Steven Verity and Farjo, {Ayad A.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.ophtha.2015.01.019",
language = "English (US)",
volume = "122",
pages = "1085--1095",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Mitomycin-C in corneal surface excimer laser ablation techniques

T2 - A report by the American academy of ophthalmology

AU - Majmudar, Parag A.

AU - Schallhorn, Steven C.

AU - Cason, John B.

AU - Donaldson, Kendall E.

AU - Kymionis, George D.

AU - Shtein, Roni M.

AU - Verity, Steven

AU - Farjo, Ayad A.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective To review the published literature assessing the efficacy and safety of mitomycin-C (MMC) as an adjunctive treatment in corneal surface excimer laser ablation procedures. Methods Literature searches of the PubMed and Cochrane Library databases were last conducted on August 19, 2014, without language or date limitations. The searches retrieved a total of 239 references. Of these, members of the Ophthalmic Technology Assessment Committee Refractive Management/Intervention Panel selected 26 articles that were considered to be of high or medium clinical relevance, and the panel methodologist rated each article according to the strength of evidence. Ten studies were rated as level I evidence, 5 studies were rated as level II evidence, and the remaining 11 studies were rated as level III evidence. Results The majority of the articles surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation procedures. When MMC is applied in the appropriate concentration and confined to the central cornea, the incidence of post-surface ablation haze is decreased. Although a minority of studies that evaluated endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcomes were reported. Conclusions Over the past 15 years, the use of MMC during surgery in surface ablation has become widespread. There is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against haze in higher myopic ablations. Although there are reports of decreased endothelial counts after the administration of MMC during surgery, the clinical significance of this finding remains uncertain, because no adverse outcomes were reported with as much as 5 years of follow-up. Optimal dosage, effectiveness as prophylaxis in lower myopic and hyperopic ablations, and long-term safety, particularly in eyes with reduced corneal endothelial cell counts from prior intraocular surgery, have yet to be established.

AB - Objective To review the published literature assessing the efficacy and safety of mitomycin-C (MMC) as an adjunctive treatment in corneal surface excimer laser ablation procedures. Methods Literature searches of the PubMed and Cochrane Library databases were last conducted on August 19, 2014, without language or date limitations. The searches retrieved a total of 239 references. Of these, members of the Ophthalmic Technology Assessment Committee Refractive Management/Intervention Panel selected 26 articles that were considered to be of high or medium clinical relevance, and the panel methodologist rated each article according to the strength of evidence. Ten studies were rated as level I evidence, 5 studies were rated as level II evidence, and the remaining 11 studies were rated as level III evidence. Results The majority of the articles surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation procedures. When MMC is applied in the appropriate concentration and confined to the central cornea, the incidence of post-surface ablation haze is decreased. Although a minority of studies that evaluated endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcomes were reported. Conclusions Over the past 15 years, the use of MMC during surgery in surface ablation has become widespread. There is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against haze in higher myopic ablations. Although there are reports of decreased endothelial counts after the administration of MMC during surgery, the clinical significance of this finding remains uncertain, because no adverse outcomes were reported with as much as 5 years of follow-up. Optimal dosage, effectiveness as prophylaxis in lower myopic and hyperopic ablations, and long-term safety, particularly in eyes with reduced corneal endothelial cell counts from prior intraocular surgery, have yet to be established.

UR - http://www.scopus.com/inward/record.url?scp=84930039537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930039537&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2015.01.019

DO - 10.1016/j.ophtha.2015.01.019

M3 - Article

C2 - 25795477

AN - SCOPUS:84930039537

VL - 122

SP - 1085

EP - 1095

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 6

ER -